AstraZeneca and the Memorial Sloan Kettering Cancer Center (MSK) have tapped digital health tech company IgniteData to provide an automated data capture tool for a phase 3 clinical trial.
IgniteData’s tool, called Archer, automatically sends data from electronic health records at hospitals directly to sponsors, according to a March 31 press release, allowing for fast and error-free data transfer and removing the need for manual data entry.
“The implementation of Archer in this AstraZeneca-sponsored phase 3 study demonstrates the growing industry-academia alignment on the future of trial data management,” Joe Lengfellner, senior director of clinical research information technology at the MSK, said in the release. “This convergence will accelerate trial execution and improve data quality across the clinical research ecosystem.”
IgniteData is shooting Archer into a full phase 3 trial following a successful pilot program of the tool, the company said in the release. IgniteData plans to continually learn from each deployment of Archer to refine the tool so that it can be launched more broadly to research sites around the world.
IgniteData isn’t the only tech firm looking to expand the use of an automated data capture tool. Flatiron Health, an independent affiliate of the Roche Group, recently forged a pact with NRG Oncology to leverage its Flatiron Clinical Pipe for a multicenter cancer trial.
Meanwhile, MSK is no stranger to tech partnerships. The cancer center inked a deal with Absci in August 2024 to develop up to six oncology antibodies using artificial intelligence.